Login
Arena Pharmaceuticals NASDAQ: ARNA
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients. Its investigative drug candidates include olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases
| Name | Arena Pharmaceuticals |
| Ticker | ARNA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Price | 65.50 |
| 52W Low/High | 34.83 / 87.71 |
| Market cap | 3.8 B |
| 1Y Total Return |
34.50%
Strong |
| 1Y Volatility |
56.59%
Average Risk |
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients. Its investigative drug candidates include olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases
Details
| Ticker | ARNA |
| Name | Arena Pharmaceuticals |
| ISIN | CA0400451062 |
| CUSIP | 040045106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 11/25/20
| Close Price | 65.50 |
| 52W Low/High | 34.83 / 87.71 |
| Market cap | 3.8 B |
| 1Y Total Return |
34.50%
Strong |
| 1Y Volatility |
56.59%
Average Risk |
| Beta | 0.40 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -11,293.7% |
| Cash from Op. / Cur. Liabilities | -5.94 |
| Diluted Earnings / Share | -7.00 |
| ROE | - |
| ROIC | -40.8% |
| Price / Revenue | 1,152.4 |
| Price / Book | 3.2 |
| Price / CF | -12.3 |
| Current Ratio | 23.2 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.04 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
3
|
812
|
25
|
60
|
21
|
40
|
|
| Gross Profit |
3
|
812
|
25
|
69
|
22
|
27
|
|
| R&D |
298
|
195
|
98
|
60
|
70
|
96
|
|
| EBITDA |
-363
|
563
|
-102
|
-32
|
-80
|
-93
|
|
| Operating Income |
-385
|
532
|
-114
|
-28
|
-85
|
-104
|
|
| Net Income exc. Extra |
-
|
555
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
58
|
50
|
49
|
38
|
24
|
24
|
|
| EPS exc. Extra |
-7.00
|
10.89
|
-2.68
|
-0.95
|
-3.82
|
-4.70
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
1,276
|
1,242
|
610
|
348
|
210
|
286
|
|
| Cash, Eq & Invt ShortTerm |
1,168
|
784
|
562
|
279
|
102
|
181
|
|
| Total Current Assets |
1,202
|
806
|
572
|
304
|
135
|
200
|
|
| Total Non-Current Assets |
73
|
436
|
38
|
44
|
75
|
86
|
|
| Intangibles |
0
|
0
|
0
|
2
|
8
|
8
|
|
| Total Liabilities |
106
|
96
|
79
|
130
|
206
|
204
|
|
| Total Current Liabilities |
52
|
37
|
22
|
69
|
61
|
48
|
|
| Long Term Debt |
54
|
59
|
57
|
61
|
146
|
156
|
|
| Shareholder equity |
1,170
|
1,146
|
531
|
219
|
3
|
82
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-308
|
596
|
-105
|
-69
|
-78
|
-96
|
|
| Depreciation |
4
|
3
|
4
|
1
|
5
|
10
|
|
| Cash from Investing |
259
|
-945
|
-51
|
1
|
0
|
-11
|
|
| Capex |
3
|
3
|
1
|
1
|
10
|
11
|
|
| Cash from Financing |
338
|
10
|
385
|
245
|
-2
|
101
|
|
| Stock Issued |
341
|
13
|
389
|
248
|
1
|
103
|
|
| Debt (LT) Issued |
-4
|
-3
|
-4
|
-3
|
-3
|
-2
|
|
| Free Cash Flow |
-894
|
470
|
-176
|
-25
|
-88
|
-112
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
68.3%
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
112.1%
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
23.2
|
21.9
|
26.1
|
4.4
|
2.2
|
4.2
|
|
| Financial Leverage D/E |
0.04
|
0.04
|
0.11
|
0.29
|
19.85
|
0.84
|
|
| Return on Capital Avg |
-40.8%
|
100.6%
|
-265.7%
|
-135.9%
|
-161.2%
|
-187.5%
|
|
| Return on Shareholder Equity |
-
|
66.1%
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available